Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey B Travers

Showing results (141-150 of 144) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 144 results.
The Journal of Clinical Investigation|April 8, 2021
Keratinocyte-derived microvesicle particles mediate ultraviolet B radiation-induced systemic immunosuppressionLangni Liu, Azeezat A Awoyemi, Katherine E Fahy, et al.
Human Gene Therapy. Clinical Development|July 13, 2013
From bench to bedside: preclinical evaluation of a self-inactivating gammaretroviral vector for the gene therapy of X-linked chronic granulomatous diseaseStefan Stein, Simone Scholz, Joachim Schwäble, et al.
The Lancet. Oncology|October 27, 2012
Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trialKent A Robertson, Grzegorz Nalepa, Feng-Chun Yang, et al.
Journal for Immunotherapy of Cancer|October 2, 2021
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrenceCraig L Slingluff, Karl D Lewis, Robert Andtbacka, et al.
Pageof 15

Showing results (141-150 of 144) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 144 results.
The Journal of Clinical Investigation|April 8, 2021
Keratinocyte-derived microvesicle particles mediate ultraviolet B radiation-induced systemic immunosuppressionLangni Liu, Azeezat A Awoyemi, Katherine E Fahy, et al.
Human Gene Therapy. Clinical Development|July 13, 2013
From bench to bedside: preclinical evaluation of a self-inactivating gammaretroviral vector for the gene therapy of X-linked chronic granulomatous diseaseStefan Stein, Simone Scholz, Joachim Schwäble, et al.
The Lancet. Oncology|October 27, 2012
Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trialKent A Robertson, Grzegorz Nalepa, Feng-Chun Yang, et al.
Journal for Immunotherapy of Cancer|October 2, 2021
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrenceCraig L Slingluff, Karl D Lewis, Robert Andtbacka, et al.
Pageof 15